Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Breast Adenocarcinoma|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Recurrent Breast Carcinoma|Stage IV Breast Cancer
Interventions: DRUG: Rebastinib|DRUG: Paclitaxel|DRUG: Eribulin Mesylate
Sponsor: Montefiore Medical Center
Collaborators: Deciphera Pharmaceuticals LLC|Albert Einstein College of Medicine